SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on June 06, 2022 for Raksha Sudhir Valia Sun Pharma to expand field force in India by 10% this fiscal
The company is driven by objectives of brand focus and geographical expansion. SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst / Institutional Investor Meeting SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Transcript of the Company's Q4FY22 earnings conference call.
Specialty business set to spur growth for Sun Pharma in next 3 yrs: Experts
Global specialty drug sales for Sun Pharma have grown by 39% YoY in FY22 to $674 million 
Sun Pharma shares fall after Q4 loss. Here's what analysts recommend
Sun Pharma shares plunged over 4% on the BSE in Tuesday's trading session
Sun Pharma slips 4% on posting Rs 2,277 crores loss in Q4
The loss came on account of settlement charges of pending litigations in the US, and restructuring operations in some countries. Adjusted profit grew 18 per cent year on year (YoY) to Rs 1,582 crore.
Earnings Call for Q4FY22 of Sun Pharmaceutical Industries
Conference Call with Sun Pharmaceutical Industries Management and Analysts on Q4FY22 Performance and Outlook. Listen to the full earnings transcript. SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Q4FY22 Earnings Call Audio Recording